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Abstract
Deregulation of Src kinases is associated with cancer. We previously showed that SrcDN
conditional expression in MCF7 cells reduces tumorigenesis and causes tumor regression
in mice. However, it remained unclear whether SrcDN affected breast cancer stem cell func-
tionality or it reduced tumor mass. Here, we address this question by isolating an enriched
population of Breast Cancer Stem Cells (BCSCs) from MCF7 cells with inducible expression
of SrcDN. Induction of SrcDN inhibited self-renewal, and stem-cell marker expression
(Nanog, Oct3-4, ALDH1, CD44). Quantitative proteomic analyses of mammospheres from
MCF7-Tet-On-SrcDN cells (data are available via ProteomeXchange with identifier
PXD017789, project DOI: 10.6019/PXD017789) and subsequent GSEA showed that
SrcDN expression inhibited glycolysis. Indeed, induction of SrcDN inhibited expression and
activity of hexokinase, pyruvate kinase and lactate dehydrogenase, resulting in diminished
glucose consumption and lactate production, which restricted Warburg effect. Thus, c-Src
functionality is important for breast cancer stem cell maintenance and renewal, and stem
cell transcription factor expression, effects linked to glucose metabolism reduction.
Introduction
Mammary gland stem cells are capable of self-renewal and to generate all differentiated prog-
eny of the gland [1, 2]. Because of their long lifespan, they can accumulate mutations to
become breast cancer stem cells (BCSCs). BCSCs are slow dividing and represent 1–2% of a
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tumor biopsy; nevertheless, they reproduce the tumor upon transplantation in nude mice [3].
Breast tumors exhibiting basal phenotype, like the triple negative breast cancers (TNBC), are
usually highly metastatic with poor prognosis, resistance to chemotherapy, and are similar to
the earliest mammary gland progenitor cells, supporting the hypothesis that therapeutic failure
results from inefficient BCSCs targeting [4]. In contrast, luminal A human mammary epithe-
lial cells produce tumors in a hormone-dependent manner. As they express estrogen and pro-
gesterone receptors, but not HER2 (human epidermal growth factor 2), and they are poorly
/non-metastatic, the MCF7 cell line is a cellular model representative of this type of mammary
tumors [5].
The Src-family tyrosine kinases (SFKs) acts as intracellular mediators for signaling path-
ways from growth factors, estrogen and cytokine receptors activation, etc., mediating pathways
involved in proliferation, survival, differentiation, adhesion, migration, and invasion [6–8].
SFKs is overexpressed and/or aberrantly activated in human tumors [7, 9, 10]. In breast cancer,
SFKs has been associated with induction, progression, and metastasis [8, 11–16]. c-Src has
been involved in glycolysis regulation and Warburg effect [17–20], which is the elevated rate of
glycolysis and lactate production in aerobic conditions by tumor cells [21]. As initially shown,
c-Src/v-Src phosphorylates several glycolytic enzymes, including enolase and lactate dehydro-
genase (LDH) [22]. In 3T3 fibroblast, v-src transfection leads to increased expression of glu-
cose uptake [23]. c-Src phosphorylates Y10-LDH, increasing its activity, which promotes
invasion, anoikis resistance, and metastasis of breast cancer cells [19]. Similarly, c-Src phos-
phorylates hexokinase 1 and 2 (HK1, HK2) augmenting their activity, which stimulates glycol-
ysis, cell proliferation, migration, invasion, and tumorigenesis [20]. In human glioblastoma
U87 and U251 cells, EGFR activation leads to c-Src stimulation and subsequent Y59-Cdc25A
phosphorylation, which dephosphorylates pyruvate kinase (PKM2), promoting its interaction
with β-catenin, its transactivation and Myc transcription that induces Glut-1 (glucose trans-
porter 1), PKM2 and LDHA expression and, consequently, the Warburg effect and tumorigen-
esis [18].
We previously showed in MCF7 cells that conditional Tet-On expression of SrcDN (Src-
Dominant Negative) leads to inhibition of proliferation, attachment, spreading and migration
in cultured cells. Inoculation of cells in nude mice generates tumors, while induction of SrcDN
expression significantly reduces their tumorigenesis, and causes regression when induced in
established tumors [24]. The Src-DN is a chicken paralog of c-Src with two mutations (c-Src-
K295M/Y527F). The mutation K295M prevent binding of ATP to c-Src, avoiding its tyrosine
kinase activity, the second point mutation Y527F at the C-terminal of the molecule, that is
phosphorylated by CSK (C-terminal Src Kinase), provokes that c-Src is forced to maintain its
open conformation, which implies full functionality of the SH2 and SH3 domains [6–8].
Here we addressed the question as to whether interfering SFKs functionality by SrcDN
expression directly affects MCF7-BCSC renewal. Thus, here we isolate by FACS the enriched
population of BCSCs (ESA+-CD44+-CD24-/Low cells, from now on CD24-) and the so-called
tumor-differentiated cells (ESA+-CD44+-CD24+ cells, from now on CD24+) from MCF7-Tet-
On-SrcDN [24], and test their capacity of self-renewal. Our findings show that c-Src is impor-




Information about antibodies used in these experiments is in S2 Table in S1 File (Antibodies).
BCA protein assay (Termofisher); Acrylamide/bis 40% solution, 29:1 (3.3% C), ammonium
PLOS ONE c-Src controls breast cancer stem cells
PLOS ONE | https://doi.org/10.1371/journal.pone.0235850 July 16, 2020 2 / 17
accession number: PXD017789, project DOI: 10.
6019/PXD017789).
Funding: This work has been supported by grand
SAF2016–75991-R (MINECO, AEI/FEDER, UE) to
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persulfate and clarity immunoblot ECL substrate (Bio-Rad); trypan blue, doxycycline (Doxy),
BSA, puromycin, and insulin (Sigma-Aldrich); EGF, and bFGF (PeproTech EC Ltd., London,
UK); G418, versene, and trypsin (Invitrogen); tetracycline-free fetal bovine serum (Tet-Free-
FCS, PAA Laboratories GmbH). Other chemical reagents and enzymes used were of analytical
grade and purchased from Roche, GE Healthcare, or Sigma-Aldrich/Merck.
Cells and culture
MCF7 (HTB-22) were from ATCC. Cells were mycoplasma free and authenticated by short-
tandem-repeat analysis (GenePrintR 10 System from Promega, and GeneMapper v3.7 STR
profile analysis software, Life Technologies) (see Supplementary Information). Profiles
obtained were checked against public databases ATCC and DSMZ. MCF7-Tet-On-SrcDN
cells bearing a Doxy-inducible SrcDN (avian c-Src-K295M/Y527F) were previously generated
[24] and maintained in DMEM, 5% Tet-Free-FCS, 2 mM glutamine, 100 IU/mL penicillin,
100 μg/mL streptomycin, and 0.2 mg/mL G418, 0.5 μg/mL puromycin for selection.
Isolation and culture of CD24- and CD24+ subpopulations from MCF7
cells
The enriched subpopulations of CD24- and CD24+ cells derived from MCF7-Tet-On-SrcDN
were isolated by fluorescence-activated cell sorting (FACS), as described [3]. Briefly, 1x107
cells were detached from the culture plates with versene (5 min, 37˚C), and then simulta-
neously labeled with antibodies to ESA-FITC, CD44-APC, CD24-PE, and with their respective
isotypic immunoglobulins. Cells were washed and subjected to FACS with a FACS-Vantage
cell sorter (BD, San Jose CA) equipped with an argon ion laser (emission at 488 nm) and a He-
Ne laser (emission at 633 nm). Cells were gated on forward and side scatters properties and
specific fluorescent signals were collected using 530 nm (FITC), 575 nm (PE) and 660 nm
(APC) bandpass filters. About 1.6% of the cell population showed the CD24- (ESA+-CD44+-
CD24-) phenotype and were isolated. In parallel, the CD24+ (ESA+-CD44+-CD24+) cells were
also isolated as described [3].
CD24- cells were maintained in mammosphere media (1:1 DMEM/HAM’S F12, 2 mM glu-
tamine, 100 IU/mL penicillin, 100 mg/mL streptomycin, 5 μg/mL Insulin, 20 ng/mL EGF, 10
ng/mL bFGF, 4 mg/ml BSA), and 0.2 mg/mL G418, 0.5 μg/mL puromycin to maintain selec-
tion for c-SrcDN expression [24], and they were grown in suspension in 6-multiwell ultralow
attachment plates (Falcon 351146, BD); CD24+ cells were cultured in DMEM, 5% Tet-Free-
FCS, 2 mM glutamine, 100 IU/mL penicillin, 100 mg/mL streptomycin, and 0.2 mg/mL of
G418 and 0.5 μg/mL puromycin in standard plates (Falcon, BD). Also, another protocol was
employed for BCSCs enrichment to enrich for BCSCs from MCF7-Tet-On-SrcDN, single cells
obtained after trypsinization of adherent cultures were plated at 1x103 cells/mL and cultured
as described above for CD24- [25].
Sphere Formation Efficiency (SFE)
SFE from MCF7-Tet-On-SrcDN was determined as described [26]. Briefly, single cell suspen-
sions of adherent cultures were plated in 6-well ultralow attachment plates (Falcon, Corning
Life Science) at 2x103 cells/well and maintained in serum-free DMEM/F12 media (1:1), BSA (4
mg/mL), EGF (20 ng/mL) and bFGF (20 ng/mL), insulin (5 μg/mL), hydrocortisone (5 μg/
mL) to obtain mammospheres. Fifteen days later, mammospheres were dissociated into single
cells that were plated in 6-well ultralow attachment plates at 2x103 cells/well in mammosphere
culture media, 3 wells without Doxy (Control) and 3 wells with Doxy (2 μg/mL). During the
experiments Doxy was renewed every 3 days in cultures. Each mammosphere generation was
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cultured about 15 days. Mammospheres (sphere-like structures with diameter� 50 μm) were
clearly detected by optical phase contrast microscope (Nikon-Eclipse TS100, 4x magnifica-
tion). For mammosphere dissociation, they were collected in a sterile tube and allow them to
sediment, the media was removed with a pipette and trypsinized in Tris-Saline pipetting up
and down to facilitate mammosphere dissociation, cells were then collected by centrifugation
to remove trypsin, washed with mammosphere media and counted. Single cells were seeded
again for mammosphere formation in 6-well ultralow attachment plates at 2x103 cells/well.
The experiment ended at 3rd generation of mammosphere formation. The cells were growth in
absence (Control) or presence (Doxy) of 2 μg/ml Doxy for three generations, and renewed
every three days. SFE was calculated as number of spheres formed per number of seeded cells
and expressed as % means ± SD. The SFE experiments were repeated 5 times, each one of
them was carried out in triplicates (p<0.05�).
Immunohistochemistry of mammospheres
Mammospheres derived from MCF7-Tet-On-SrcDN were fixed in 4% formaldehyde solution.
Fixed samples were paraffin embedded, and 5 μm sections were analyzed by hematoxylin/
eosin, and E-cadherin and P-cadherin staining were performed using Envision method [27].
Immunoblotting analysis
Preparation of cell lysates from mammospheres and immunoblotting analyses were carried
out as previously described [24]. Briefly, mammospheres were collected by centrifugation at
200xg 5 min at room temperature, washed twice with cool PBS and lysed at 4˚C with lysis
buffer [10 mM Tris–HCl (pH 7.6), 50 mM NaCl, 30 mM sodium pyrophosphate, 5 mM
EDTA, 5 mM EGTA, 0.1% SDS, 1% Triton X-100, 50 mM NaF, 0.1 mM Na3VO4, 1 mM
PMSF, 1 mM benzamidine, 1 mM iodoacetamide and 1 mM phenantroline]. Cell lysates were
obtained by centrifugation at 21,380xg for 30 min at 4˚C; protein concentration in the super-
natant was determined by BCA protein assay (Pierce, Rockford, IL), and lysates were adjusted
to equivalent concentrations with lysis buffer. Aliquots of 10–40 μg of total cell lysate were
then separated on SDS–PAGE. Proteins were transferred to PVDF membranes that were
blocked overnight at 4˚C with 5% non-fat milk in TTBS (TBS with 0.05% Tween-20). Incuba-
tion with primary specific antibodies was carried out overnight at 4˚C, and horseradish peroxi-
dase-conjugated secondary antibodies in blocking solution for 1 h at room temperature.
Immunoreactive bands were visualized by ECL kit.
Quantitative proteomic analysis
Briefly, MCF7-Tet-On-SrcDN derived mammospheres at 3rd generation from two indepen-
dent experiments cultured either in the absence (Control) or presence of Doxy (2 μg/mL) were
collected by centrifugation, washed with PBS, and lysed in 9 M urea, 2 M thiourea, 5%
CHAPS, and 2 mM TCEP. The samples were precipitated by methanol/chloroform and quan-
tified by Pierce 660nm Protein Assay. Then 30 μg of protein from each sample were trypsi-
nized, and the resulting peptides were labeled using iTRAQ 4-plex reagent (SCIEX, Foster
City, CA, USA) according to the manufacturer’s instructions and named as follows: Control-1,
114-tag; Doxy-1, 115-tag; Control-2, 116-tag; Doxy-2, 117-tag. Samples were pooled, evapo-
rated to dryness and frozen. The pool was separated into 5 fractions in a reverse phase C18
chromatography at basic pH and cleaned with a StageTip-C18. The 5 fractions were quantified
by fluorimetry, and 1 μg of each fraction was separated by C-18 reverse phase chromatography
during 150 min. The eluted peptides passed then into 5600 Triple-TOF MS (SCIEX, Foster
City, CA). The raw data of the combined 5 fractions was exported to the search-engine Mascot
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Server v2.5.1 (Matrix Science, London, UK) confronted to the Homo sapiens UniProt database.
Peptide mass tolerance was set to ± 25 ppm for precursors and 0.05 Da for fragment masses.
Frequency distribution histograms of protein ratios were obtained into Excel 2010. Log2 pep-
tide ratios followed a normal distribution that was fitted using least squares regression. Mean
and standard deviation values derived from the Gaussian fit were used to calculate p-values
and quantification of False Discovery Rates (FDR). The confidence interval for protein identi-
fication was set to� 95% (p<0.05) and only peptides with an individual ion score above the
1% False Discovery Rates (FDR) threshold were considered correctly identified. Only proteins
having at least two quantitated peptides were considered in the quantitation. A 5% quantita-
tion FDR threshold was estimated to consider the significant differentially expressed proteins.
The mass spectrometry proteomics data have been deposited to the ProteomeXchange
Consortium via the PRIDE [28] partner repository (Project accession number: PXD017789,
project DOI:10.6019/PXD017789).
Enzymatic activity assays
Mammospheres at 3rd generation derived from MCF7-TET-ON-SrcDN cells were seeded into
a six-well plate and cultured with fresh medium -/+ Doxy (2 μg/mL) for 12–24 h. Cells were
harvested by centrifugation, washed twice with PBS and preincubated for 10 min in PBS.
Then, cells were collected by centrifugation, suspended in fresh culture medium and incubated
for another 4 h. Cells were harvested by centrifugation at room temperature at 0 and 4 h incu-
bation and treated with 200 μL lysis buffer (Tris-HCl (pH 7.5), 1 mM EDTA, 0.5 mM dithio-
threitol, 0.2% Triton X-100, 0.2 mg/mL deoxycholate, 0.2 mM phenylmethylsulfonyl fluoride,
and 2.5 μg/mL leupeptin), and homogenized at 4˚C by pipetting up and down. The homoge-
nate was centrifuged at 21,380xg for 15 min at 4˚C and the supernatant was used for enzymatic
activity measurements. Hexokinase (HK) activity was determined spectrophotometrically at
340 nm by following the G6PDH dependent conversion of NADP to NADPH. The assay mix-
ture contained 100 mM Tris-HCl (pH 8.0), 0.5 mM EDTA, 10 mM MgCl2, 5 mM MgATP, 2
mM glucose, 0.5 mM NADP+ and 10 U/mL glucose 6-phosphate dehydrogenase (G6PDH) in
a final volume of 1 mL. HK activities were calculated according to the slope of the resulting
curves in the log phase. The initial velocity of lactate dehydrogenase (LDH) was determined by
measuring spectrophotometrically the NADH consumption at 340 nm in a 1 mL reaction mix-
ture (50 mM HEPES pH 7.2, 100 mM KCl, 5 mM MgCl2, 0.15 mM NADH, and 2 mM pyru-
vate). The slopes of the initial linear decrease were used to calculate initial velocities. Pyruvate
kinase (PK) activity was measured by following the production of pyruvate. The reaction mix-
ture consisted of 50 mM HEPES (pH 7.2), 100 mM KCl, 5 mM MgCl2, 0.15 mM NADH, 1
mM MgADP, 2 mM phosphoenolpyruvate, and 1 U/mL of LDH as the auxiliary enzyme in a
final volume of 1 mL. PK activity was determined spectrophotometrically as above by record-
ing the change of 340 nm absorbance produced by NADH oxidation. One unit of enzyme
activity is defined as the amount of enzyme catalyzing the conversion of 1 μmol of substrate/
min at 25˚C. Enzymatic activities of different samples were normalized against the corre-
sponding protein concentrations in the lysates.
Lactate production and glucose consumption assays
Cells were treated as above. At 0 and 4 h incubation, cells were harvested by centrifugation at
room temperature, and the culture medium was removed and stored at -70˚C for lactate pro-
duction and glucose consumption measurements. Cell pellets were homogenized in ice-cold
8% (v/v) perchloric acid in 40% ethanol. After centrifugation at 21,380xg for 15 min at 4˚C, the
supernatant was neutralized to pH 7.0 with a 2 M KOH and 0.5 M triethanolamine solution,
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the mixture was incubated on ice for 15 min, and precipitated KClO4 was removed by centrifu-
gation. Glucose and lactate content in culture medium and levels of intracellular lactate were
assessed by using standard enzymatic techniques [29]. Briefly, lactate was determined in a
reaction containing 0.5 M Glycine, 0.2 M hydrazine, 3.4 mM EDTA, 1.5 mM NAD+, and 10
U/mL of LDH, pH 9.5. The reaction mixture for glucose measurement consisted of 0.1 M
triethanolamine, 5 mM MgCl2, 0.5 mM NADP
+, 1 mM ATP, 1 U/mL hexokinase and 3 U/mL
G6PD, pH 7.4. The function of the glycolytic pathway was evaluated by the amount of lactate
produced per hour after 4 h incubation. Glucose consumption rate (per hour) was calculated
considering the difference between the amount in the medium at 0 h and that recovered in the
medium after 4 h incubation. Glucose and lactate content were normalized to the protein con-
centration of cells cultured under similar conditions and obtained as described above for enzy-
matic activity.
Oxygen consumption and determination of ATP concentration
Mammospheres at 3rd generation cultured in the absence or presence of 2 μg/mL Doxy were
dissociated to single-cell suspension as for SFE, resuspended in mammospheres media with or
without pyruvate and without BSA to 106 cells/mL and the oxygen consumption of 2x106 cells
was measured by high-resolution respirometry with the OROBOROS oxygraph-2k in a stan-
dard configuration, at 37˚C and a 750-rpm stirrer speed as described [30]. The protocol
includes the determination in a sequential manner of the aerobic metabolic activity under rou-
tine culture conditions with the physiological substrates in culture medium (Cr), the oligomy-
cin-inhibited leak rate of respiration after inhibition of ATP synthase with 2 μg/mL
oligomycin (CrO) and the maximum respiratory capacity of uncoupled mitochondria in non-
permeabilized cells (CrU), obtained by sequential addition of 0.5 μM boluses of trifluoro-car-
bonylcyanide phenylhydrazone (FCCP). The protonophore FCCP dissipates the proton inner
membrane gradient making ETC to function at its maximal rate since oxygen and protons are
not limiting for the ETC Complex IV catalysis. All values, including physiological conditions
and the maximal respiratory capacity, are derived by subtracting non- mitochondrial respira-
tion from the FCCP rate.
Measurements of total ATP concentration were made in mammospheres that were main-
tained for at least 15 days -/+ Doxy (2 μg/mL) at 0 and 4 h, as previously described [31], follow-
ing instructions of the ATP Bioluminescence Assay Kit CLS II (Roche, Ref. 11699695001).
Statistical analyses
Mean values, standard deviation and statistical significance between data from two different
experimental conditions were determined by two-tail Student t-test. In all figures, data repre-
sent the Mean from at least three separate biological repeats done in at least triplicates
each ± SD (standard deviation), �p<0.05, ��p< 0.01, and ���p< 0.001.
Results
Isolation and characterization of an enriched population of BCSCs from
MCF7 cells
To determine the role of SrcDN in the self-renewal of the enriched subpopulation of BCSCs,
we isolated CD24- (ESA+-CD44+-CD24-) and CD24+ (ESA+-CD44+-CD24+) cell populations
derived from MCF7-Tet-On-SrcDN by FACS. Cells were first sorted as ESA+ and then for
being CD44+-CD24- (1.6%), while the CD44+-CD24+ represented 98.4% of total cell popula-
tion (Fig 1A, isotype controls shown in S1 Fig in S1 File). CD24- cells formed mammospheres
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Fig 1. Cell sorting of CD24- and CD24+ subpopulations of MCF7 cells. (A) Histograms of ESA-FITC positive cells that were
later sorted for CD44-APC positive and CD24-PE negative (1.6%). (B) Microphotograph under light microscope of
mammospheres from CD24- cells in culture. Representative images of spheres stained with hematoxylin/eosin, E-cadherin or
P-cadherin. Scales bars are included. (C) Immunoblot of total c-Src, SrcDN, p-Y397-Fak/Fak, and E-cadherin, using α-Tubulin
PLOS ONE c-Src controls breast cancer stem cells
PLOS ONE | https://doi.org/10.1371/journal.pone.0235850 July 16, 2020 7 / 17
(Fig 1B) that after staining with hematoxylin/eosin showed a monolayer cell-structure with
their nuclei oriented towards the lumen. Furthermore, mammospheres expressed E-cadherin,
but not P-cadherin (Fig 1B). These results suggested that both CD24- (mammospheres) and
CD24+ cells maintained the epithelial phenotype of the MCF7 total population.
To determine the functionality of SrcDN, protein extracts from mammospheres from
CD24- and from CD24+ cell subpopulations were blotted for pY397-Fak, showing an increased
phosphorylation upon SrcDN induction. This is consistent with previous results showing that
SH2 domain from SrcDN binds pY397-Fak protecting from dephosphorylation [24, 32, 33],
and with the reduction of pY925-Fak, p-Y-p130CAS, pY118-Paxillin phosphorylation by c-Src
in MCF7 cells [24]. Expression of E-cadherin remained unaltered in CD24- and CD24+ upon
SrcDN induction (Fig 1C). SrcDN expression was tested by detecting total c-Src and avian
SrcDN (Fig 1C).
c-Src functionality is necessary for mammospheres self-renewal
To characterize the role of c-Src in the enriched subpopulation of BCSC self-renewal, we ana-
lyzed whether induction of SrcDN expression altered formation of mammospheres from
MCF7-Tet-On-SrcDN. Self-renewal capacity was confirmed by three successive generations of
mammospheres, where a progressive enrichment of mammosphere-forming cells (CD24-) was
observed (S2 Fig in S1 File). Then, we determined Sphere Formation Efficiency (SFE) upon
induction of SrcDN expression from the first generation and found that it significantly
reduced SFE as compared to control (-Doxy) at the 3rd generation (Fig 2A). This effect was
expression as loading control from CD24- cells forming mammospheres and CD24+ cells in absence (Control) or presence of
Doxy (2 μg/mL) for induction of SrcDN during three passages. The ratios of the proteins Total c-Src, SrcDN, and E-cadherin
with the loading control α-Tubulin, or pY397-Fak/Fak were calculated and referred to -Doxy (Control) considered as 1. These
are representative results from 3 independent experiments.
https://doi.org/10.1371/journal.pone.0235850.g001
Fig 2. Self-renewal of mammospheres derived from MCF7. (A) The Sphere Formation Efficiency (SFE) was determined in MCF7-Tet-On-SrcDN. Thus,
single cell suspensions from adherent cells were plated in 6-well ultralow attachment plates at 2x103 cells/well and cultured in mammosphere medium. Fifteen
days later, mammospheres were dissociated into single cells that were divided into two groups: Control (-Doxy) and Doxy treated (2 μg/mL). Doxy-treatment
was maintained for three generations, and renewed every 3 days. SFE at 3rd generation was calculated as number of spheres formed per number of seeded cells
and expressed as % means ± SD. The SFE experiments were repeated 5 times, each one of them was carried out in triplicates. (p<0.05�). (B) Total cell extracts
from the 3rd generation of mammospheres treated as above (panel A) were used to determine by immunoblotting expression of cyclin D1, PARP, with α-
Tubulin, as a loading control, and SrcDN, Nanog, Oct3/4, ALDH1, and CD44, employing GAPDH or β-Actin, as a loading control. The net quantification of
the gel bands after subtracting the background was carried out with ImageJ program and expressed in arbitrary units. These are representative results from 3
independent experiments. The ratios of the proteins SrcDN, Nanog, Oct3/4, ALDH1, and CD44 and their loading controls GAPDH or ß-Actin, or
pY10-LDHA/LDHA were calculated and referred to -Doxy (Control) considered as 1.
https://doi.org/10.1371/journal.pone.0235850.g002
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clearly evident from the 1st generation (S2 Fig in S1 File), although no morphological alter-
ations were observed upon SrcDN induction (data not shown). Consistently, cyclin D1 expres-
sion at the 3rd generation was also reduced. However, SrcDN expression did not appear to
cause apoptosis, as PARP degradation was undetectable. To determine the nature of cells that
form mammospheres, we have dissociated mammospheres at the 3rd generation, labelled cells
with anti-CD24-PE and CD44-APC monoclonal antibodies, as well as with isotypic immuno-
globulins for control, and analyzed them by flow cytometry. S3 Fig in S1 File showed that in
control mammospheres most of cells are CD44+-CD24-. In contrast, in Doxy-treated mammo-
spheres a large number of cells were CD44+-CD24+. In addition, the analysis of the expression
level of these markers (MFC, mean fluorescence channel) indicates that, along with an increase
of expression of CD24, treated mammospheres show a reduced expression of CD44. More-
over, expression of pluripotency-related transcription factors involved in self-renewal Nanog,
Oct3/4, and stem cell markers ALDH1, and CD44 [34–36] were also reduced (Fig 2B).
Together, these results suggested that c-Src functionality is relevant for MCF7-mammosphere
renewal.
Proteomic analyses of mammospheres
Since c-Src functionality is important for SFE of MCF7-mammospheres, we analyzed whether
SrcDN induction quantitatively modified protein expression. Proteomic analyses identified
2,759 proteins with at least two peptides, full data available at Proteome Xchange database
(project accession number: PX017789, project DOI: 10.6019/PX017789). From those, only 101
proteins were differentially expressed with an FDR < 5% (S1 Table in S1 File). In the Fig 3
only proteins having at least two quantitated peptides and<5% quantitation FDR with the
same tendency in both experiments were included. Thus, induction of SrcDN by Doxy (2 μg/
mL) diminished the levels of fifteen proteins, and increased the levels of four of them (Fig 3,
and S4 Fig in S1 File). The most increased protein in Doxy/Control is c-Src, which most likely
should correspond to SrcDN induced by Doxy-treated mammospheres, as the identity of
Homo Sapiens and Gallus-Gallus c-Src at the amino acid sequences is 94%. Results obtained
were submitted to GSEA and found that glycolysis was significantly reduced in MCF7-
mammospheres upon SrcDN induction (S5 Fig in S1 File), which was consistent with data
from Fig 3.
Fig 3. Quantitative proteomic analysis of mammospheres derived from MCF7-Tet-On-SrcDN. The analysis was carried out in two independent
experiments from the total cell extract of the 3rd generation mammospheres either untreated (Control) or Doxy-treated. Only proteins having at
least two quantitated peptides and<5% quantitation FDR in both experiments are included in the figure.
https://doi.org/10.1371/journal.pone.0235850.g003
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Role of c-Src in the regulation of glycolysis in MCF7-mammospheres
As glycolytic pathway was inhibited in mammospheres upon SrcDN induction, we investi-
gated whether glucose consumption was altered, and found that it was significantly reduced in
mammospheres expressing SrcDN (Fig 4A), which parallels a reduction in Glut-1 levels (Fig
4D), the major glucose transporter in tumor cells [37]. In cancer cells, Src enhances HK enzy-
matic activity, a rate-limiting enzyme of glycolysis, by direct phosphorylation [20]. Since
SrcDN is a kinase-dead mutant and competes with endogenous Src kinases [38], HK enzy-
matic activity was significantly inhibited in Doxy-treated mammospheres (Fig 4C). In addi-
tion, HK2 levels were also diminished (Fig 4D), supporting proteomic results (Fig 3).
However, we were unable to detect HK2 tyrosine phosphorylation. Similarly, PKM enzymatic
activity was also inhibited upon SrcDN expression (Fig 4C). In head and neck and in breast
cancer cells, Src phosphorylates and enhances LDHA [19]. We tested for SrcDN effects on
LDHA enzymatic activity, expression, and phosphorylation. In Doxy-treated mammospheres,
LDH activity was significantly reduced (Fig 4C), as it was pY10-LDHA/LDHA ratio (Fig 4D).
It is well established that c-Myc and HIF-1 promote the expression of enzymes implicated in
glycolysis regulation, including HK2 and LDHA [39, 40, 41]. Thus, we analyzed c-Myc and
HIF-1 expression level in Control (Doxy-untreated) and Doxy-treated (2 μg/mL) 3rd mammo-
sphere generations by SYBR Green-q-RT-PCR and by immunoblotting (see Supplementary
Material). SrcDN induction did not modify c-Myc expression both at RNA and protein level
while HIF-1 RNA expression was significantly reduced. In addition, we were not able to detect
HIF-1 protein expression by immunoblotting as the protein is extremely labile (S6 Fig in S1
File). The decrease in glucose consumption was paralleled by a nearly stoichiometric reduction
of lactate production (lactate/glucose ratio of 1.45 ± 0.12 and 1.58 ± 0.09 for wild-type and
SrcDN-mammospheres, respectively). Thus, the production of lactate from glutaminolysis is
very limited. Interestingly, although lactate production diminished, intracellular accumulation
of this metabolite was increased (Fig 4B), a result consistent with the reduced expression of
MCT-1 (SLC16A1, proton coupled monocarboxylate transporter 1) in Doxy-treated mammo-
spheres (Fig 4D), the major lactate transporter in tumor cells [42].
Effects of SrcDN on oxygen consumption and ATP production
Results showed that SrcDN expression inhibited glycolysis and altered the lactate levels in
mammospheres. We next determined the effects of SrcDN in mitochondrial respiration capac-
ity, either in culture without pyruvate, and in normal culture media, which containing saturat-
ing concentrations of pyruvate to the uncoupled mitochondria to glycolysis, pushing oxygen
consumption to its highest. Basal oxygen consumption of cells dissociated from mammo-
spheres in media containing pyruvate was unmodified by SrcDN expression, while the maxi-
mum was significantly inhibited (Fig 5A). Similarly, oxygen consumption carried out in media
without pyruvate was also unaltered in basal conditions, but the maximum was highly reduced
in mammospheres expressing SrcDN (Fig 5A, and S7 Fig in S1 File: OCR profiles). Further-
more, analyses of ATP production did not differ between cells dissociated from mammo-
spheres expressing SrcDN and control cells (Fig 5B). Neither alteration in ROS level, nor
modification of catalase or MnSOD expression was observed upon SrcDN induction in mam-
mospheres, as compared to controls (Doxy-untreated) (S8 Fig in S1 File).
Discussion
Cancer stem cells, which represent only a small subpopulation in a tumor, possess the ability
of self-renewal and to form new tumors in nude mice. In breast cancer, BCSCs are defined by
expression of ESA, CD44 and low CD24 expression (ESA+/CD44+/CD24-), and high
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Fig 4. Expression of SrcDN reduced glycolysis in MCF7 mammosphere-derived cells. Control and Doxy-treated (2 μg/mL) mammospheres from the 3rd
generation were used to study glycolysis. (A) Determination of glucose consumption. (B) Lactate production, intracellular lactate. (C) Enzymatic activity of
hexokinase (HK), pyruvate kinase (PK), lactate dehydrogenase (LDH). (���p<0.001). (D) Expression of Glut-1, total c-Src, HK2, pY10-LDHA, LDHA, and
MCT-1, was determined by immunoblotting, employing ß-Actin as a loading control. These are representative results from 3 independent experiments. The
ratios refer to -Doxy considered as 1.
https://doi.org/10.1371/journal.pone.0235850.g004
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tumorigenic capabilities [3]. In this context, the low percentage of BCSCs (CD24- cells) that we
found here, correlates with previous observations [3] and confirms that the isolation of the
CD24- cells was properly done.
In this study we analyzed the effects of the induction of a dominant-negative mutant of the
protooncogene c-Src, the SrcDN. We found that disrupting c-Src pathways by induction of
SrcDN expression reduced the self-renewal capabilities (SFE) of the enriched population of
BCSCs derived from MCF7. Interestingly, cytometric analyses of SrcDN expressing mammo-
sphere cells showed a reduction of CD44 and increased CD24 expression as compared to con-
trol mammosphere cells (non-expressing SrcDN). In addition, SrcDN induction did not
induce apoptosis as PARP degradation did not occur, instead cyclin D1 expression was
reduced, while Myc expression was unaltered. In this respect, we previously observed that
SrcDN expression and selective c-Src tyrosine-kinase inhibitors diminish cyclin D1 expression
and cell cycle progression at G1-phase in breast cancer cells [24, 43, 44]. Moreover, these mam-
mosphere cells also showed expression of Oct3/4, Nanog pluripotency-associated transcription
factors, ALDH1, and CD44 stem-cell markers [34–36], which were reduced upon SrcDN
Fig 5. Effects of SrcDN on oxygen consumption, and ATP production in MCF7 mammosphere-derived cells. (A) Oxygen consumption in normal
media containing pyruvate or in media without pyruvate and (B) ATP production, they were determined in cells obtained from Control (Doxy-untreated)
and Doxy-treated (2 μg/mL) 3rd generation mammospheres.
https://doi.org/10.1371/journal.pone.0235850.g005
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induction. These pluripotency-associated transcription factors are required for embryonic
stem cell self-renewal [34], and they are also involved in tumorigenesis and metastasis [45].
Specifically, MDA-MB-231 cells exhibit high expression of Oct3/4, and low levels of Nanog
compared to MCF7 and T47D [46]. Collectively, our results suggest that c-Src functionality is
essential for the self-renewal ability of BCSCs derived from MCF7 to grow in vitro as
mammospheres.
MCF7 cells have been used as a model for Luminal A type of hormonal-dependent breast
tumors, they have epithelial characteristics, they express E-cadherin, and are low or non-meta-
static [5]. Here, we showed that mammosphere-forming cells derived from MCF7, which rep-
resented about 1.6% of total cell population, maintained their epithelial phenotype as they
showed E-cadherin, but not P-cadherin staining.
Quantitative proteomic analyses of untreated and Doxy-treated mammospheres identified
up to 2.759 proteins; of these proteins, 101 were differentially expressed (FDR < 5%), but only
19 of them showed same tendency in two independent experiments. Among those proteins, 15
showed a reduced expression upon SrcDN induction. The gene set enrichment analysis
(GSEA) of the reduced proteins revealed an inhibition of the glycolytic pathway in these
tumor-initiating cells. Thus, SrcDN restricts the Warburg effect in MCF7-mammospheres, as
it reduced expression of Glut-1, glucose consumption, and expression and activity of HK2,
PKM, LDHA, and lactate production. Since HIF-1 and Myc are known transcription factors
involved in the control of HK2 and LDHA expression [39–41], we tested whether they were
modulated by induction of SrcDN. While SrcDN inhibited expression of mRNA expression of
HIF-1, Myc expression both at mRNA and protein levels was not altered. In human colon ade-
nocarcinoma LS174T and in murine melanoma B16-F10 cell lines Warburg effect requires
expression of both LDH A and B [47]. Interestingly, while LDH B is expressed in TNBC cells,
it is undetectable in luminal A cells, such as MCF7 [48]. Since MCT-1 expression was also
inhibited upon SrcDN induction in MCF7-mammospheres, lactate accumulated intracellu-
larly. It has been recently shown that SrcDN reduced glucose catabolism required for prolifera-
tion, migration, invasion, and tumorigenesis in cancer cells [49]. c-Src phosphorylates HK1
and HK2, rate-limiting enzymes of glycolysis, and enhances their catalytic activity [20]. More-
over, c-Src also phosphorylates LDHA at Y10, increasing its activity, which correlates with
metastasis progression of clinical tumor samples of breast cancer [19], while as shown here,
the dominant-negative variant of c-Src, the SrcDN counteracted these effects. In contrast, the
basal oxygen consumption, ATP production, ROS, catalase, and MnSOD levels were unmodi-
fied by SrcDN expression in mammospheres, indicating that under basal conditions, the mito-
chondrial functionality was unaltered by SrcDN expression.
These data strongly suggest that c-Src functionality is important for the self-renewal capac-
ity in MCF7 breast cancer stem cells, linked to glucose metabolism.
Conclusions
The findings presented in our study support the role of c-Src in the self-renewal of the enriched
subpopulation of MCF7 breast cancer stem cells (BCSCs). Furthermore, results showed that c-
Src functionality is a requisite for BCSCs. Src regulates Warburg effect in BCSCs, which in turn
somehow controls stem-cell factors mediating stem-cell renewal. Elucidating the pathways that
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Funding acquisition: Miguel Ángel Fernández-Moreno, Jorge Martı́n-Pérez.
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H. Martı́nez-Costa, Cristina González-Páramos, Sergio Ciordia, David Hardisson, Juan J.
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Writing – original draft: Jorge Martı́n-Pérez.
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